Scroll

acetylsalicylic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	74	50-78-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acetylsalisylic acid aspirin acetylsalicylic acid aspirin sodium aspirin magnesium aspirin potassium aspirin calcium aspirin anhydride aspirin lysine	The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Molecular weight: 180.16 Formula: C9H8O4 CLOGP: 1.09 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 63.60 ALOGS: -2.09 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acetylsalisylic acid
aspirin
acetylsalicylic acid
aspirin sodium
aspirin magnesium
aspirin potassium
aspirin calcium
aspirin anhydride
aspirin lysine

The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Molecular weight: 180.16
Formula: C9H8O4
CLOGP: 1.09
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 63.60
ALOGS: -2.09
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	tablet	O
30	mg	O
3	g	O
1	g	P
3	g	R

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	4.60 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	370.22 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	1.40 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.68 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.26 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 12, 1950	FDA	ENDO PHARMS
Jan. 1, 1898	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	1523.97	11.21	9193	932420	1035572	61511837
Gastrointestinal haemorrhage	1226.69	11.21	3293	938320	77883	62469526
Myocardial infarction	1048.35	11.21	3564	938049	96329	62451080
Cerebrovascular accident	770.48	11.21	3411	938202	104613	62442796
Acute myocardial infarction	685.88	11.21	1490	940123	30634	62516775
Treatment failure	681.61	11.21	1191	940422	197852	62349557
Labelled drug-drug interaction medication error	661.45	11.21	902	940711	12497	62534912
Coronary artery disease	658.77	11.21	1473	940140	30904	62516505
Off label use	629.32	11.21	6686	934927	667776	61879633
Alopecia	618.63	11.21	2738	938875	334798	62212611

Showing 1 to 10 of 918 entries

Previous1 2 3 4 5…92Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myocardial infarction	1515.34	13.72	5878	746691	115207	34089155
Gastrointestinal haemorrhage	1441.44	13.72	4685	747884	83792	34120570
Drug ineffective	1197.74	13.72	5420	747149	451331	33753031
Coronary artery disease	1164	13.72	2946	749623	45359	34159003
Off label use	933.83	13.72	5267	747302	414257	33790105
Acute myocardial infarction	924.55	13.72	2900	749669	50819	34153543
Labelled drug-drug interaction medication error	808.86	13.72	1279	751290	13660	34190702
Drug abuse	613.28	13.72	738	751831	98358	34106004
Angina pectoris	549.34	13.72	1704	750865	29659	34174703
Upper gastrointestinal haemorrhage	544.64	13.72	1488	751081	24030	34180332

Showing 1 to 10 of 774 entries

Previous1 2 3 4 5…78Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myocardial infarction	2895.50	11.65	8374	1376398	175755	78183861
Gastrointestinal haemorrhage	2828.66	11.65	7224	1377548	140495	78219121
Coronary artery disease	1905.45	11.65	3784	1380988	61690	78297926
Drug ineffective	1876.55	11.65	11070	1373702	1069843	77289773
Acute myocardial infarction	1763.43	11.65	4038	1380734	72998	78286618
Labelled drug-drug interaction medication error	1512.46	11.65	2122	1382650	25528	78334088
Cerebrovascular accident	1250.37	11.65	5679	1379093	149613	78210003
Cardiac failure congestive	1190.27	11.65	5266	1379506	137136	78222480
Off label use	1113.31	11.65	10241	1374531	896974	77462642
Melaena	957.09	11.65	2771	1382001	58119	78301497

Showing 1 to 10 of 1,301 entries

Previous1 2 3 4 5…131Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cyst	21.21	17.52	9	1077	18	88688
Urinary tract disorder	20.30	17.52	9	1077	21	88685
Congenital acrochordon	17.62	17.52	9	1077	32	88674

Showing 1 to 3 of 3 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A01AD05	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Other agents for local oral treatment
ATC	B01AC06	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
ATC	B01AC56	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
ATC	C07FX02	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations
ATC	C07FX03	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations
ATC	C07FX04	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations
ATC	C10BX01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Lipid modifying agents in combination with other drugs
ATC	C10BX02	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Lipid modifying agents in combination with other drugs
ATC	C10BX04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Lipid modifying agents in combination with other drugs
ATC	C10BX05	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Lipid modifying agents in combination with other drugs

Showing 1 to 10 of 52 entries

Previous1 2 3 4 5 6Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Sinus headache	indication	4969004
Pain	indication	22253000
Myocardial infarction	indication	22298006	DOID:5844
Toothache	indication	27355003
Migraine	indication	37796009	DOID:6364
Joint pain	indication	57676002
Rheumatoid arthritis	indication	69896004	DOID:7148
Common cold	indication	82272006	DOID:10459
Backache	indication	161891005
Headache disorder	indication	230461009

Showing 1 to 10 of 13 entries

Previous1 2Next

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Pain	Indication
Dogs	Inflammation	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Cortaba Tablets	Zoetis Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.57	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
325MG	VAZALORE	PLX PHARMA	N203697	Jan. 14, 2013	OTC	CAPSULE	ORAL	10786444	Sept. 29, 2032	A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
325MG	VAZALORE	PLX PHARMA	N203697	Jan. 14, 2013	OTC	CAPSULE	ORAL	9226892	Sept. 29, 2032	TEMPORARY REDUCTION OF FEVER
325MG	VAZALORE	PLX PHARMA	N203697	Jan. 14, 2013	OTC	CAPSULE	ORAL	9226892	Sept. 29, 2032	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
325MG	VAZALORE	PLX PHARMA	N203697	Jan. 14, 2013	OTC	CAPSULE	ORAL	9226892	Sept. 29, 2032	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
325MG;40MG	YOSPRALA	GENUS LIFESCIENCES	N205103	Sept. 14, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	6926907	Feb. 28, 2023	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
325MG;40MG	YOSPRALA	GENUS LIFESCIENCES	N205103	Sept. 14, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	8206741	Feb. 28, 2023	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
325MG;40MG	YOSPRALA	GENUS LIFESCIENCES	N205103	Sept. 14, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	9987231	Jan. 2, 2033	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
325MG;40MG	YOSPRALA	GENUS LIFESCIENCES	N205103	Sept. 14, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	9539214	March 13, 2033	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
81MG	VAZALORE	PLX PHARMA	N203697	Feb. 26, 2021	OTC	CAPSULE	ORAL	10786444	Sept. 29, 2032	A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY
81MG;40MG	YOSPRALA	GENUS LIFESCIENCES	N205103	Sept. 14, 2016	DISCN	TABLET, DELAYED RELEASE	ORAL	6926907	Feb. 28, 2023	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS

Showing 1 to 10 of 13 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	5.12	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	5.77	WOMBAT-PK	CHEMBL
Gamma-glutamyltranspeptidase 1	Enzyme	P19440	GGT1_HUMAN		IC50	4.44	CHEMBL
Acid-sensing ion channel 3	Ion channel	Q9UHC3	ASIC3_HUMAN	BLOCKER	IC50	4	IUPHAR
Nicotinate phosphoribosyltransferase	Enzyme	Q6XQN6	PNCB_HUMAN		Ki	9.30	CHEMBL
Acidic phospholipase A2 3	Enzyme		PA2A3_NAJSG		Kd	5.20	WOMBAT-PK
Prostaglandin G/H synthase 1	Enzyme		PGH1_SHEEP		IC50	6.52	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP		IC50	5.62	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_BOVIN		IC50	6.46	CHEMBL

Showing 1 to 9 of 9 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
AIN	PDB_CHEM_ID
001587	NDDF
1191	RXNORM
132-49-0	SECONDARY_CAS_RN
1466-82-6	SECONDARY_CAS_RN
2244	PUBCHEM_CID
244	MMSL
25817-25-8	SECONDARY_CAS_RN
34512	MMSL
37933-78-1	SECONDARY_CAS_RN

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Basic Care Aspirin	HUMAN OTC DRUG LABEL	1	0113-0773	TABLET, FILM COATED	325 mg	ORAL	OTC monograph not final	15 sections
Excedrin PM Triple Action Caplets	HUMAN OTC DRUG LABEL	3	0067-2056	TABLET, COATED	250 mg	ORAL	OTC monograph not final	16 sections
Excedrin PM Triple Action Caplets	HUMAN OTC DRUG LABEL	3	0067-2056	TABLET, COATED	250 mg	ORAL	OTC monograph not final	16 sections
ExcedrinExtra Strength Geltabs	HUMAN OTC DRUG LABEL	3	0067-2021	TABLET, COATED	250 mg	ORAL	OTC monograph not final	14 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-2000	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	13 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-2000	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	13 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-2001	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	15 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-2001	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	15 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-8202	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	15 sections
ExcedrinExtra Strength Pain Reliever	HUMAN OTC DRUG LABEL	3	0067-8202	TABLET, FILM COATED	250 mg	ORAL	OTC monograph not final	15 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next